The Economic Burden of Schizophrenia in the United States in 2013

2016485 citationsJournal Article

Authors

Martin Cloutier · Group for Research in Decision Analysis

Myrlene Sanon Aigbogun · Otsuka (United States)

Annie Guérin · Group for Research in Decision Analysis

Roy Nitulescu · Group for Research in Decision Analysis

Agnihotram V. Ramanakumar · Group for Research in Decision Analysis

Siddhesh Kamat · Otsuka (United States)

Michael DeLucia

Abstract

Schizophrenia is associated with a significant economic burden where, in addition to direct health care costs, indirect and non-health care costs are strong contributors, suggesting that therapies should aim at improving not only symptom control but also cognition and functional performance, which are associated with substantial non-health care and indirect costs.

Topics & Keywords

Health Systems, Economic Evaluations, Quality of Life Pharmaceutical Economics and Policy Mental Health Treatment and Access

UN Sustainable Development Goals

Decent work and economic growth

Publication Details

Published in: The Journal of Clinical Psychiatry

Volume 77, Issue 06, pp. 764-771

DOI: 10.4088/jcp.15m10278

Field-Weighted Citation Impact: 163.38